Biosense Webster

3333 Diamond Canyon Road

Diamond Bar

91765

(909) 839-8500

(909) 468-2905

[email protected]

http://www.biosensewebster.com

Product Categories

Catheter

Related Content

A Review of the 2024 Heart Rhythm Society Conference

Feature | HRS| By Lars Thording, PhD

HRS 2024: Innovation Meets Reality

Innovation in medical technology exists to improve patient outcomes, increase surgical efficiency and enhance patient ...

June 11, 2024

Regulatory approval for the first fully integrated PFA system with a CARTO-enabled simple and reproducible workflow

News | Stroke

Biosense Webster Announces CE Mark approval in Europe for VARIPULSE Pulsed Field Ablation (PFA) Platform

March 5, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

March 05, 2024

Investigational device designed for Left Atrial Appendage Elimination (LAAX) to reduce the risk of stroke in patients with non-valvular atrial fibrillation

News | Atrial Fibrillation

Biosense Webster Begins Enrollment of Pivotal Trial Evaluating the Laminar Left Atrial Appendage Elimination Device 

February 27, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

February 27, 2024

News | Atrial Fibrillation

Biosense Webster Study Supports Low and Zero Fluoroscopy Workflow as Safe, Effective Alternative to Conventional Catheter Ablation

February 2, 2024 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

February 02, 2024

Study will evaluate investigational Dual Energy Thermocool SmartTouch SF Catheter potential to deliver safe and effective radiofrequency (RF) and pulsed field ablation (PFA)

News | Atrial Fibrillation

Biosense Webster Begins Enrollment of SmartPulse Study in the U.S. to Evaluate RF and PFA Dual Energy Catheter to Treat Atrial Fibrillation

December 22, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

December 22, 2023

$Retrospective study of over 18,000 drug-refractory AFib patients found those treated with catheter ablation had a 57% lower risk of developing heart failure compared to those receiving antiarrhythmic drugs$

News | Atrial Fibrillation

Biosense Webster Study Links Lower Risk of Heart Failure in Atrial Fibrillation Patients Treated with Catheter Ablation Compared to Antiarrhythmic Drugs

October 6, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

October 06, 2023

Study will evaluate the safety and effectiveness of the OMNYPULSE Pulsed Field Ablation (PFA) platform with integrated mapping

News | Cardiovascular Clinical Studies

Biosense Webster Begins Evaluation of Large-tip Focal Pulsed Field Ablation Catheter in Omny-IRE Clinical Trial in Europe

September 18, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & ...

September 18, 2023

SmartfIRE study is evaluating THERMOCOOL SMARTTOUCH SF Dual Energy Catheter’s potential to enable safe and simple procedures with the ability to deliver both radiofrequency (RF) and pulsed field ablation (PFA)

News | Atrial Fibrillation

Biosense Webster Completes Enrollment in Pivotal Trial Evaluating PFA and RF Dual Energy Catheter for Patients with Atrial Fibrillation in Europe

July 21, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

July 21, 2023

News | Atrial Fibrillation

Jasmina Brooks Named President of Biosense Webster

May 17, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmiatreatment and part of Johnson & Johnson ...

May 17, 2023

Presentations include data on pulsed field ablation (PFA), disparities in atrial fibrillation (AFib) management, role of mapping and digital technologies in advancing cardiac arrhythmia treatment and real-world evidence informing treatment pathways

News | EP Mapping and Imaging Systems

Biosense Webster Highlights New Research and Technology to Advance AFib Treatment at Heart Rhythm 2023

May 15, 2023 — Biosense Webster, Inc., a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson ...

May 15, 2023